MEDMIRA INC (MIR.CA) Stock Price, Forecast & Analysis
Canada - TSX-V:MIR - CA58501R1029 - Common Stock
MIR.CA Key Statistics, Chart & Performance
The current stock price of MIR.CA is 0.07 CAD. In the past month the price decreased by -22.22%. In the past year, price decreased by -6.67%.
MIR.CA Latest News, Press Relases and Analysis
MIR.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| PRN.CA | PROFOUND MEDICAL CORP | N/A | 272.89M | ||
| CNVI.CA | CONAVI MEDICAL CORP | N/A | 49.12M | ||
| TLT.CA | THERALASE TECHNOLOGIES INC | N/A | 48.32M | ||
| ASG.CA | AURORA SPINE CORP | N/A | 23.17M | ||
| PINK.CA | PERIMETER MEDICAL IMAGING AI | N/A | 21.38M | ||
| NSCI.CA | NANALYSIS SCIENTIFIC CORP | N/A | 21.24M | ||
| MDX.CA | MEDX HEALTH CORP | N/A | 16.99M | ||
| VPT.CA | VENTRIPOINT DIAGNOSTICS LTD | N/A | 15.93M | ||
| THRM.CA | THERMA BRIGHT INC | N/A | 4.54M | ||
| VVTM.CA | VVT MED INC | N/A | 20.05M |
Related stock screener links
About MIR.CA
Company Profile
MedMira, Inc. is a biotechnology company, which engages in the development and commercialization of rapid diagnostics and technology platforms. The company is headquartered in Halifax, Nova Scotia. The firm's tests provide hospitals, labs, clinics and individuals with an instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The firm is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. The company provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.
Company Info
MEDMIRA INC
155 Chain Lake Dr.,, Suite 1
Halifax NOVA SCOTIA B3S 1B3 CA
CEO: Hermes Chan
Employees: 52
Phone: 19024501588
MEDMIRA INC / MIR.CA FAQ
What does MIR do?
MedMira, Inc. is a biotechnology company, which engages in the development and commercialization of rapid diagnostics and technology platforms. The company is headquartered in Halifax, Nova Scotia. The firm's tests provide hospitals, labs, clinics and individuals with an instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The firm is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. The company provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.
What is the current price of MIR stock?
The current stock price of MIR.CA is 0.07 CAD.
Does MEDMIRA INC pay dividends?
MIR.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of MIR stock?
MIR.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the Price/Earnings (PE) ratio of MEDMIRA INC (MIR.CA)?
MEDMIRA INC (MIR.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.01).
How many employees does MEDMIRA INC have?
MEDMIRA INC (MIR.CA) currently has 52 employees.
MIR.CA Technical Analysis
MIR.CA Financial Highlights
Over the last trailing twelve months MIR.CA reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS decreased by -52.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -123.38% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |